Media Mentions
MLex Quotes Benesch Partner Paul Kremer on Why Large Patent Awards Often Fail on Appeal
October 24, 2025
Benesch Partner Paul Kremer was quoted in an MLex article titled “Study shows ‘robust’ link between patent awards, appellate outcomes.”
The article discusses a study on U.S. patent damage awards, finding that large verdicts—especially those over $500 million—rarely survive appeal. Of awards over $10 million between 2010 and 2025, only about one-third were upheld, with biotech cases faring slightly better. Low affirmance rates can influence settlement decisions and investment in patent-heavy industries, particularly given the high costs of litigation.
Paul explains that most patent cases are concentrated in Texas and Delaware, where trials are short and experts have limited time to present complex damages. This forces experts to balance a methodologically sound opinion with a compelling narrative for jurors. Overworked courts and compressed schedules prevent full exploration of damages theories, making large awards more fragile, as illustrated by the ecoFactor v. Google damages-only retrial.
More: Study shows ‘robust’ link between patent awards, appellate outcomes
Latest News
Benesch Partner Aslam Rawoof Quoted on Effective AI Governance in Industry Article
Benesch Partner Aslam Rawoof was recently quoted in an article discussing the challenges organizations face when implementing and governing artificial …
Law360 Highlights Benesch Team Representing Gould Electronics in California Environmental Cleanup Matter
Law360 recently reported on a California federal judge’s approval of a $27.5 million cost-allocation agreement in litigation related to groundwater …
Benesch Co-Chair Margo Wolf O’Donnell Quoted in Footwear News on Employment Law Challenges
Margo Wolf O’Donnell, Co-Chair of the firm’s Labor & Employment Practice Group, was quoted in a recent Footwear News article …
Benesch Partner Tara Raghavan Quoted in Law360 on Federal Circuit’s Wyeth Patent Ruling
Benesch Intellectual Property Partner Tara Raghavan was quoted in a recent Law360 article discussing the Federal Circuit’s decision invalidating Wyeth LLC’s cancer treatment patents based on a lack of enablement.